Ramesh K. Ramanathan
University of Pittsburgh Cancer Institute
Pittsburgh
PA 15213
USA
Name/email consistency: high
- Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Ramanathan, R.K., Hwang, J.J., Zamboni, W.C., Sinicrope, F.A., Safran, H., Wong, M.K., Earle, M., Brufsky, A., Evans, T., Troetschel, M., Walko, C., Day, R., Chen, H.X., Finkelstein, S. Cancer Invest. (2004)
- Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. Ramanathan, R.K., Clark, J.W., Kemeny, N.E., Lenz, H.J., Gococo, K.O., Haller, D.G., Mitchell, E.P., Kardinal, C.G. J. Clin. Oncol. (2003)
- Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patients. Ramanathan, R.K., Potter, D.M., Belani, C.P., Jacobs, S.A., Gravenstein, S., Lim, F., Kim, H., Savona, S., Evans, T., Buchbarker, D., Simon, M.B., Depee, J.K., Trump, D.L. J. Clin. Oncol. (2002)
- Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ramanathan, R.K., Cnaan, A., Hahn, R.G., Carbone, P.P., Haller, D.G. Ann. Oncol. (2001)
- Dramatic response of adult wilms tumor to paclitaxel and cisplatin. Ramanathan, R.K., Rubin, J.T., Ohori, N.P., Belani, C.P. Med. Pediatr. Oncol. (2000)
